ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000432

Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward

Identifieur interne : 000432 ( PascalFrancis/Corpus ); précédent : 000431; suivant : 000433

Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward

Auteurs : Andrew H. Evans ; Andrew D. Lawrence ; Silke Appel Cresswell ; Regina Katzenschlager ; Andrew J. Lees

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0288348

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Traitement.

English descriptors

KwdEn :
- Nervous system diseases, Parkinson disease, Treatment.

Abstract

A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use ("dopamine dysregulation syndrome"-DDS). DDS patients commonly identify aversive dysphoric "OFF" mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the "OFF"-state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full "ON"-state was achieved. In the "OFF"-state, DDS patients reported lower positive affect, and more motor and non-motor disability. In the "ON"-state, DDS patients had higher expressions of drug "wanting," reward responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward`
A11	`01`	`1`		`@1 EVANS (Andrew H.)`
A11	`02`	`1`		`@1 LAWRENCE (Andrew D.)`
A11	`03`	`1`		`@1 CRESSWELL (Silke Appel)`
A11	`04`	`1`		`@1 KATZENSCHLAGER (Regina)`
A11	`05`	`1`		`@1 LEES (Andrew J.)`
A14	`01`			`@1 Department of Neurology, The Royal Melbourne Hospital @2 Parkville, Victoria @3 AUS @Z 1 aut.`
A14	`02`			`@1 Department of Medicine, University of Melbourne @2 Victoria @3 AUS @Z 1 aut.`
A14	`03`			`@1 Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery @2 Queen Square, London @3 GBR @Z 1 aut. @Z 4 aut. @Z 5 aut.`
A14	`04`			`@1 Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University @2 Cardiff @3 GBR @Z 2 aut.`
A14	`05`			`@1 Pacific Parkinson's Research Centre, University of British Columbia @2 Vancouver, British Columbia @3 CAN @Z 3 aut.`
A14	`06`			`@1 Department of Neurology, Donauspital/SMZ-Ost @2 Vienna @3 AUT @Z 4 aut.`
A20				`@1 867-876`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000193040220080`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 44 ref.`
A47	`01`	`1`		`@0 10-0288348`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use ("dopamine dysregulation syndrome"-DDS). DDS patients commonly identify aversive dysphoric "OFF" mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the "OFF"-state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full "ON"-state was achieved. In the "OFF"-state, DDS patients reported lower positive affect, and more motor and non-motor disability. In the "ON"-state, DDS patients had higher expressions of drug "wanting," reward responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 186`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0288348 INIST
ET :	Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward
AU :	EVANS (Andrew H.); LAWRENCE (Andrew D.); CRESSWELL (Silke Appel); KATZENSCHLAGER (Regina); LEES (Andrew J.)
AF :	Department of Neurology, The Royal Melbourne Hospital/Parkville, Victoria/Australie (1 aut.); Department of Medicine, University of Melbourne/Victoria/Australie (1 aut.); Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery/Queen Square, London/Royaume-Uni (1 aut., 4 aut., 5 aut.); Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University/Cardiff/Royaume-Uni (2 aut.); Pacific Parkinson's Research Centre, University of British Columbia/Vancouver, British Columbia/Canada (3 aut.); Department of Neurology, Donauspital/SMZ-Ost/Vienna/Autriche (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 7; Pp. 867-876; Bibl. 44 ref.
LA :	Anglais
EA :	A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use ("dopamine dysregulation syndrome"-DDS). DDS patients commonly identify aversive dysphoric "OFF" mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the "OFF"-state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full "ON"-state was achieved. In the "OFF"-state, DDS patients reported lower positive affect, and more motor and non-motor disability. In the "ON"-state, DDS patients had higher expressions of drug "wanting," reward responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Traitement
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Treatment
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Tratamiento
LO :	INIST-20953.354000193040220080
ID :	10-0288348

Links to Exploration step

Pascal:10-0288348

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward</title>
<author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, The Royal Melbourne Hospital</s1>
<s2>Parkville, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine, University of Melbourne</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lawrence, Andrew D" sort="Lawrence, Andrew D" uniqKey="Lawrence A" first="Andrew D." last="Lawrence">Andrew D. Lawrence</name>
<affiliation><inist:fA14 i1="04"><s1>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University</s1>
<s2>Cardiff</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cresswell, Silke Appel" sort="Cresswell, Silke Appel" uniqKey="Cresswell S" first="Silke Appel" last="Cresswell">Silke Appel Cresswell</name>
<affiliation><inist:fA14 i1="05"><s1>Pacific Parkinson's Research Centre, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation><inist:fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Donauspital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288348</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288348 INIST</idno>
<idno type="RBID">Pascal:10-0288348</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000432</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward</title>
<author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, The Royal Melbourne Hospital</s1>
<s2>Parkville, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine, University of Melbourne</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lawrence, Andrew D" sort="Lawrence, Andrew D" uniqKey="Lawrence A" first="Andrew D." last="Lawrence">Andrew D. Lawrence</name>
<affiliation><inist:fA14 i1="04"><s1>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University</s1>
<s2>Cardiff</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cresswell, Silke Appel" sort="Cresswell, Silke Appel" uniqKey="Cresswell S" first="Silke Appel" last="Cresswell">Silke Appel Cresswell</name>
<affiliation><inist:fA14 i1="05"><s1>Pacific Parkinson's Research Centre, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation><inist:fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Donauspital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use ("dopamine dysregulation syndrome"-DDS). DDS patients commonly identify aversive dysphoric "OFF" mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the "OFF"-state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full "ON"-state was achieved. In the "OFF"-state, DDS patients reported lower positive affect, and more motor and non-motor disability. In the "ON"-state, DDS patients had higher expressions of drug "wanting," reward responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>EVANS (Andrew H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LAWRENCE (Andrew D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CRESSWELL (Silke Appel)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KATZENSCHLAGER (Regina)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LEES (Andrew J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, The Royal Melbourne Hospital</s1>
<s2>Parkville, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine, University of Melbourne</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University</s1>
<s2>Cardiff</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Pacific Parkinson's Research Centre, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Donauspital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>867-876</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193040220080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0288348</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use ("dopamine dysregulation syndrome"-DDS). DDS patients commonly identify aversive dysphoric "OFF" mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the "OFF"-state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full "ON"-state was achieved. In the "OFF"-state, DDS patients reported lower positive affect, and more motor and non-motor disability. In the "ON"-state, DDS patients had higher expressions of drug "wanting," reward responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>186</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0288348 INIST</NO>
<ET>Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward</ET>
<AU>EVANS (Andrew H.); LAWRENCE (Andrew D.); CRESSWELL (Silke Appel); KATZENSCHLAGER (Regina); LEES (Andrew J.)</AU>
<AF>Department of Neurology, The Royal Melbourne Hospital/Parkville, Victoria/Australie (1 aut.); Department of Medicine, University of Melbourne/Victoria/Australie (1 aut.); Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery/Queen Square, London/Royaume-Uni (1 aut., 4 aut., 5 aut.); Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University/Cardiff/Royaume-Uni (2 aut.); Pacific Parkinson's Research Centre, University of British Columbia/Vancouver, British Columbia/Canada (3 aut.); Department of Neurology, Donauspital/SMZ-Ost/Vienna/Autriche (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 7; Pp. 867-876; Bibl. 44 ref.</SO>
<LA>Anglais</LA>
<EA>A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use ("dopamine dysregulation syndrome"-DDS). DDS patients commonly identify aversive dysphoric "OFF" mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the "OFF"-state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full "ON"-state was achieved. In the "OFF"-state, DDS patients reported lower positive affect, and more motor and non-motor disability. In the "ON"-state, DDS patients had higher expressions of drug "wanting," reward responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Traitement</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Treatment</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Tratamiento</SD>
<LO>INIST-20953.354000193040220080</LO>
<ID>10-0288348</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000432 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000432 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0288348
   |texte=   Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward

Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri